66.90
전일 마감가:
$67.59
열려 있는:
$67.8
하루 거래량:
2.57M
Relative Volume:
0.47
시가총액:
$210.86B
수익:
$54.07B
순이익/손실:
$7.04B
주가수익비율:
29.67
EPS:
2.255
순현금흐름:
$7.28B
1주 성능:
-1.63%
1개월 성능:
-10.72%
6개월 성능:
-13.61%
1년 성능:
-2.41%
아스트라제네카 ADR Stock (AZN) Company Profile
명칭
Astrazeneca PLC
전화
44 20 3749 5000
주소
1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge
AZN을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
AZN
Astrazeneca PLC
|
66.90 | 210.86B | 54.07B | 7.04B | 7.28B | 2.255 |
아스트라제네카 ADR Stock (AZN) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-04-15 | 개시 | Exane BNP Paribas | Outperform |
2025-02-13 | 업그레이드 | UBS | Neutral → Buy |
2025-02-12 | 개시 | Morgan Stanley | Overweight |
2024-11-20 | 업그레이드 | UBS | Sell → Neutral |
2024-11-06 | 업그레이드 | Deutsche Bank | Sell → Hold |
2024-09-13 | 다운그레이드 | Deutsche Bank | Hold → Sell |
2024-05-30 | 개시 | Goldman | Buy |
2024-04-16 | 업그레이드 | Deutsche Bank | Sell → Hold |
2024-02-08 | 다운그레이드 | Deutsche Bank | Hold → Sell |
2024-01-23 | 개시 | Morgan Stanley | Overweight |
2024-01-16 | 재개 | UBS | Sell |
2024-01-03 | 다운그레이드 | Jefferies | Buy → Hold |
2023-12-18 | 개시 | HSBC Securities | Buy |
2023-09-25 | 업그레이드 | Jefferies | Hold → Buy |
2023-07-14 | 개시 | HSBC Securities | Buy |
2023-07-12 | 업그레이드 | UBS | Neutral → Buy |
2023-07-05 | 다운그레이드 | Deutsche Bank | Buy → Hold |
2023-04-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2023-01-05 | 개시 | BMO Capital Markets | Outperform |
2022-09-15 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
2022-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2022-08-29 | 업그레이드 | Argus | Hold → Buy |
2022-06-14 | 다운그레이드 | UBS | Buy → Neutral |
2022-02-11 | 업그레이드 | DZ Bank | Sell → Hold |
2021-12-07 | 다운그레이드 | Jefferies | Buy → Hold |
2021-08-12 | 재개 | JP Morgan | Overweight |
2021-04-12 | 다운그레이드 | Argus | Buy → Hold |
2021-03-16 | 업그레이드 | Jefferies | Hold → Buy |
2021-02-25 | 업그레이드 | UBS | Neutral → Buy |
2021-01-15 | 개시 | Deutsche Bank | Buy |
2020-12-07 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
2020-11-30 | 업그레이드 | UBS | Sell → Neutral |
2020-11-11 | 업그레이드 | HSBC Securities | Reduce → Hold |
2020-09-29 | 개시 | Berenberg | Buy |
2019-11-22 | 개시 | SVB Leerink | Outperform |
2019-10-25 | 업그레이드 | Liberum | Hold → Buy |
2019-04-02 | 다운그레이드 | UBS | Neutral → Sell |
2019-02-05 | 개시 | Exane BNP Paribas | Outperform |
2019-01-25 | 업그레이드 | Shore Capital | Hold → Buy |
2018-12-11 | 재개 | Jefferies | Hold |
2018-10-09 | 개시 | Guggenheim | Buy |
2018-08-16 | 다운그레이드 | Jefferies | Buy → Hold |
2018-03-19 | 업그레이드 | Jefferies | Hold → Buy |
2018-02-06 | 재확인 | Leerink Partners | Mkt Perform |
2018-02-05 | 재확인 | Bernstein | Outperform |
2018-01-18 | 재확인 | Leerink Partners | Mkt Perform |
2017-12-29 | 업그레이드 | JP Morgan | Neutral → Overweight |
2017-10-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
2017-09-25 | 업그레이드 | Exane BNP Paribas | Neutral → Outperform |
2017-09-22 | 업그레이드 | Bernstein | Mkt Perform → Outperform |
모두보기
아스트라제네카 ADR 주식(AZN)의 최신 뉴스
Malignant Pleural Mesothelioma Market Poised for Growth Across the 7MM During the Study Period (2020–2034) Amid Advances in Immunotherapy and Targeted Drugs | DelveInsight - GlobeNewswire Inc.
Press Release Distribution & PR Platform - ACCESS Newswire
Omeprazole Market Is Booming Worldwide 2025-2032 | Astrazeneca Plc., Sandoz, Inc., Mylan N.V. - openPR.com
Should You Buy, Sell Or Hold AstraZeneca Stock Before Q1 Earnings? - Barchart.com
AstraZeneca's Enhertu, pertuzumab combo improves breast cancer treatment in trial - Seeking Alpha
Should You Buy, Sell or Hold AstraZeneca Stock Before Q1 Earnings? - Yahoo
AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients - Yahoo Finance
ENHERTU Plus Pertuzumab Demonstrated Highly Statistically Significant And Clinically Meaningful Improvement In Progression-Free Survival Versus. THP As 1st-Line Therapy For Patients With HER2+ Metastatic Breast Cancer - marketscreener.com
AstraZeneca (AZN) Highlights Promising Trial Results for Enhertu in Breast Cancer Treatment | AZN Stock News - GuruFocus
AstraZeneca Touts Positive Survival Data for Enhertu Combo in Broad Breast Cancer Population - marketscreener.com
AstraZeneca, Daiichi Sankyo's Breast Cancer Drug Shows High-level Results in Late-stage Trial - marketscreener.com
Vasculitis Market Overall Study Report 2025-2032 | AstraZeneca - openPR.com
AstraZeneca Unit Hit With Antitrust Suit Over Soliris - Law360
AstraZeneca Subsidiary Accused of Soliris Drug Market Monopoly - Bloomberg Law News
AstraZeneca unit sued over alleged monopoly on blockbuster drug Soliris - Reuters
AstraZeneca Unit Faces US Class Action Lawsuit Alleging Misuse of Soliris Patent - marketscreener.com
AstraZeneca Should Get Fired Worker’s Vaccine Bias Case Trimmed - Bloomberg Law News
BNP Paribas Exane sets AstraZeneca stock to outperform, PT at GBP115 - Investing.com UK
Is AstraZeneca PLC (AZN) the Best Pharma Stock to Buy for Long Term Growth? - Insider Monkey
European pharma companies issue demands to stay in EU ahead of expected US tariffs - MarketScreener
Stock Watch: Disappointing ACC Share Price Reactions For AstraZeneca And Lilly - insights.citeline.com
AstraZeneca Pharma India surrenders marketing authorisation for specific indication of Olaparib - Medical Dialogues
Is AstraZeneca (AZN) The Best UK Stock to Buy According to Billionaires? - Yahoo Finance
The Zacks Analyst Blog AbbVie's, Rinvoq and AstraZeneca's and Novartis - Nasdaq
AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica
AstraZeneca : India's Serum Institute asks government for $403 million to boost AstraZeneca vaccine output - marketscreener.com
NICE recommends new combination breast cancer drug - MarketScreener
astrazeneca shareholders approve all resolutions at agm - Investing.com
Astrazeneca PLC Says All Resolutions Passed At AGM - MarketScreener
AstraZeneca’s AGM Approves All Resolutions, Marks Board Changes - TipRanks
Drug Tariffs Will Harm Patients, AstraZeneca Chairman Says - Bloomberg.com
AstraZeneca (AZN) Gains Momentum with EU Drug Approvals - GuruFocus
AstraZeneca's quarterly earnings may undershoot; tariffs and a trade war pose the bigger obstacle - Proactive financial news
AstraZeneca and GSK retain defensive qualities, but tariff assault on sector could change that - Proactive Investors
GLP-1 Market Top PlayersAstraZeneca, Biolingus, Boehringer Ingelheim, D&D Pharmatech. - openPR.com
Down 28% in 8 months, is AstraZeneca’s share price too cheap for me to pass up right now? - Yahoo
AstraZeneca (AZN) Gains EU Nod for Imfinzi Combo in NSCLC Treatm - GuruFocus
AstraZeneca (AZN) Gains EU Approval for Expanded Enhertu Use in Breast Cancer - GuruFocus
AstraZeneca Settles Covid-Shot Suit With Christian Salesman - Bloomberg Law News
AstraZeneca Blocks Generics Ahead Of Patent Dispute - Law360
Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today - Mitrade
AstraZeneca stock touches 52-week low at $61.76 - Investing.com
AstraZeneca stock touches 52-week low at $61.76 By Investing.com - Investing.com India
UK Regulator Approves Expanded Use of AstraZeneca's Targeted Cancer Therapy - MarketScreener
UK Approves Indication Extension for AstraZeneca-Daiichi Sankyo's Cancer Drug Enhertu - marketscreener.com
Barclays Keeps AstraZeneca at Overweight on Potential to Withstand Tariff Storm - MarketScreener
AstraZeneca (AZN) Prepares for Upcoming Earnings Amid Stock Decl - GuruFocus
Trending tickers: Apple, Advanced Micro Devices, Ford, BP and AstraZeneca - Yahoo
FTSE 100 sinks as tariffs kick in with 104% for China; AstraZeneca and GSK slumpMarket Report - Proactive financial news
AstraZeneca's Camizestrant Shows Promise in SERENA-6 Breast Canc - GuruFocus
Trump inflicts £14bn blow to the UK drug sector with tariff threat - Proactive Investors
아스트라제네카 ADR (AZN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):